Loprazolam

Structural formula
General
Non-proprietary name	Loprazolam
other names	(2 Z ) -6- (2-chlorophenyl) -2 - [(4-methyl-1-piperazinyl) methylene] -8-nitro-2,4-dihydro-1 H -imidazo [1,2- a ] [ 1,4] benzodiazepin-1-one
Molecular formula	C 23 H 21 ClN 6 O 3
External identifiers / databases
PubChem	3033860
ChemSpider	2298440
DrugBank	DB13643
Wikidata	Q411806
Drug information
ATC code	N05 CD11
properties
Molar mass	464,90 g · mol -1
Melting point	214-215 ° C ; 205–210 ° C (monomesilate)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Loprazolam is a benzodiazepine of medium duration of action. Its mono mesilate is used . The indications, contraindications and interactions correspond to those of all benzodiazepines. Psychological and physical dependence can develop after only a short period of use. Monopreparations include Dormonoct, Havlane, Sonin, Somnovit (in various forms up to 2 mg). Loprazolam is mainly used as a hypnotic but also as a sedative . In Germany, the last preparation with loprazolam (Sonin) was withdrawn from the market in January 2006.

dose

The dose of loprazolam for insomnia is usually 1 mg, but it can be increased to 2 mg if necessary.

Side effects

The side effects are basically the same as for other benzodiazepines. The most common occurrences with loprazolam are:

Somnolence
Paradoxically, increased aggression
dizziness
confusion
Muscle weakness
Ataxia (especially in the elderly)
amnesia
a headache
Hypotension
Visual disturbances
Dysarthria
tremor
altered libido
Jaundice
skin rash
Dependency

Legal status

Loprazolam was included in Appendix III of the Narcotics Act (BtMG) (marketable and prescription narcotics) in the Federal Republic of Germany due to its listing . This does not apply to preparations that contain up to 2.5 mg of loprazolam per divided form without any other substance from Annexes I – III. Further information can be found in the main article Narcotics Law in Germany .

literature

McInnes GT, Bunting EA, Ings RM, Robinson J, Ankier SI. Pharmacokinetics and pharmacodynamics following single and repeated nightly administrations of loprazolam, a new benzodiazepine hypnotic. Br J Clin Pharmacol . 1985 May; 19 (5): 649-56. PMID 2860916

Individual evidence

↑ ^a ^b ^c Entry on loprazolam. In: Römpp Online . Georg Thieme Verlag, accessed on July 13, 2019.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Pharmaceutical newspaper 50, 12/05.
↑ Narcotics Act, Annex III, accessed on October 3, 2010.

[römpp-1] Entry on loprazolam. In: Römpp Online . Georg Thieme Verlag, accessed on July 13, 2019.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] Pharmaceutical newspaper 50, 12/05.

[4] Narcotics Act, Annex III, accessed on October 3, 2010.